| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
41,040,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Bionentus is a global medical device holding company focused on developing and commercializing clinically differentiated, cost efficient and minimally invasive treatments that engage and enhance the body's natural healing process. Co.'s portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, which is comprised of non-surgical joint pain injection therapies as well as peripheral nerve stimulation products; Surgical Solutions, which is comprised of bone graft substitutes to fuse and grow bones, improve results following spinal and other orthopedic surgeries; and Restorative Therapies, which is comprised of an Ultrasonic bone healing system.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
2,670,149 |
2,670,149 |
| Total Buy Value |
$0 |
$0 |
$7,192,124 |
$7,192,124 |
| Total People Bought |
0 |
0 |
4 |
4 |
| Total Buy Transactions |
0 |
0 |
17 |
17 |
| Total Shares Sold |
18,262 |
18,262 |
18,656 |
39,703 |
| Total Sell Value |
$93,362 |
$93,362 |
$94,477 |
$124,770 |
| Total People Sold |
3 |
3 |
3 |
5 |
| Total Sell Transactions |
6 |
6 |
7 |
18 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Neels Guido J |
Director |
– • – |
2022-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,700 |
11,700 |
|
- |
|
| Nohra Guy P |
Director |
– • – |
2022-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,700 |
11,700 |
|
- |
|
| Sutter Martin P |
Director |
– • – |
2022-04-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,700 |
11,700 |
|
- |
|
| Pavesio Alessandra |
SVP & Chief Science Officer |
• – – |
2022-02-14 |
4 |
AS |
$11.99 |
$5,192 |
D/D |
(433) |
119,830 |
|
- |
|
| Dadamio Anthony |
SVP & General Counsel |
• – – |
2022-02-14 |
4 |
AS |
$11.99 |
$15,513 |
D/D |
(1,294) |
18,672 |
|
- |
|
| Anglum Gregory O. |
SVP & CFO |
• – – |
2022-02-14 |
4 |
AS |
$11.99 |
$15,518 |
D/D |
(1,294) |
55,013 |
|
- |
|
| Nosenzo John |
Chief Commercial Officer |
• – – |
2022-02-14 |
4 |
AS |
$11.99 |
$6,401 |
D/D |
(534) |
43,370 |
|
- |
|
| Dadamio Anthony |
SVP & General Counsel |
• – – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,400 |
19,966 |
|
- |
|
| Stalnecker Susan M |
Director |
– • – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Pavesio Alessandra |
SVP & Chief Science Officer |
• – – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,470 |
120,263 |
|
- |
|
| Nohra Guy P |
Director |
– • – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Hawkins William A |
Director |
– • – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,500 |
51,788 |
|
- |
|
| Anglum Gregory O. |
SVP & CFO |
• – – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,400 |
56,307 |
|
- |
|
| Nosenzo John |
Chief Commercial Officer |
• – – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,470 |
43,904 |
|
- |
|
| Sutter Martin P |
Director |
– • – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Cowdy Philip G. |
Director |
– • – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Neels Guido J |
Director |
– • – |
2022-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Hawkins William A |
Director |
– • – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,288 |
38,288 |
|
- |
|
| Nosenzo John |
CHIEF COMMERCIAL OFFICER |
• – – |
2022-02-10 |
4 |
A |
$12.88 |
$311,760 |
D/D |
24,205 |
42,434 |
|
- |
|
| Nosenzo John |
CHIEF COMMERCIAL OFFICER |
• – – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,139 |
66,639 |
|
- |
|
| Anglum Gregory O. |
SVP & CFO |
• – – |
2022-02-10 |
4 |
A |
$12.88 |
$253,401 |
D/D |
19,674 |
51,907 |
|
- |
|
| Anglum Gregory O. |
SVP & CFO |
• – – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
65,581 |
71,581 |
|
- |
|
| Dadamio Anthony |
SVP & General Counsel |
• – – |
2022-02-10 |
4 |
A |
$12.88 |
$84,995 |
D/D |
6,599 |
15,566 |
|
- |
|
| Dadamio Anthony |
SVP & General Counsel |
• – – |
2022-02-10 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,165 |
22,165 |
|
- |
|
| Pavesio Alessandra |
SVP & CHIEF SCIENCE OFFICER |
• – – |
2022-02-10 |
4 |
A |
$12.88 |
$952,025 |
D/D |
73,915 |
118,793 |
|
- |
|
111 Records found
|
|
Page 4 of 5 |
|
|
